المؤلفون: Pliarchopoulou, K., Kalogeras, K. T., Kronenwett, R., Wirtz, R. M., Eleftheraki, A. G., Batistatou, Anna, Bobos, M., Soupos, N., Polychronidou, G., Gogas, H., Samantas, E., Christodoulou, C., Makatsoris, T., Pavlidis, Nicholas, Pectasides, Dimitrios, Fountzilas, George

المساهمون: Pavlidis, Nicholas [0000-0002-2195-9961]

المصدر: Cancer chemotherapy and pharmacology

مصطلحات موضوعية: Oncology, Survival rate, Scoring system, Messenger rna, Cell, Toxicology, Breast cancer, Antineoplastic Combined Chemotherapy Protocols, Pharmacology (medical), Rac gtpase activating protein 1 gene, Ki-67 antigen, Quantitative analysis, Disease free survival, Survival time, Gene expression regulation, GTPase-Activating Proteins, Prognosis, Gene Expression Regulation, Neoplastic, Survival Rate, Retrospective study, Paclitaxel, Reverse transcription polymerase chain reaction, Regression Analysis, Human, medicine.medical_specialty, Major clinical study, Nottingham prognostic index, Disease-Free Survival, Article, Cancer grading, Randomized controlled trials as topic, Disease association, Humans, RNA, Messenger, Cyclophosphamide, Retrospective Studies, Aged, Pharmacology, Cancer prognosis, Patient Selection, medicine.disease, Retrospective studies, Drug effect, Ki-67 Antigen, Methotrexate, Gene identification, chemistry, Protein expression, Risk factor, Gene expression, Breast neoplasms, Cancer Research, Unclassified drug, Messenger, Metastasis, Qrt-pcr, Cancer risk, chemistry.chemical_compound, Randomized controlled trial (topic), Patient selection, Guanosine triphosphatase activating protein, Overall survival, Gtpase-activating proteins, Middle aged, Reverse transcriptase polymerase chain reaction, Randomized Controlled Trials as Topic, Priority journal, Risk assessment, Reverse Transcriptase Polymerase Chain Reaction, Middle Aged, Primary tumor, medicine.anatomical_structure, Real-time polymerase chain reaction, Nottingham Prognostic Index, Female, Fluorouracil, Protein determination, Regression analysis, Prognostic value, Ki67, Epirubicin, medicine.drug, Adult, Proportional hazards models, Disease-free survival, Histopathology, Breast Neoplasms, Young Adult, Antineoplastic combined chemotherapy protocols, Internal medicine, medicine, Early cancer, Human tissue, Racgap1, Oncogene, Proportional Hazards Models, Neoplastic, business.industry, Cancer survival, High risk patient, Young adult, Multivariate analysis, Rac gtpase activating protein 1, Multivariate Analysis, Rna, Ki 67 antigen, Prediction, business, Controlled study, Gene function

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4aeaf136db5f1bc63a52f742e8828fd7Test
https://doi.org/10.1007/s00280-012-2002-zTest

المؤلفون: Briassoulis, E. Ch, Samantas, E., Kalofonos, H. P., Skarlos, Dimosthenis V., Makatsoris, T., Christodoulou, C., Fountzilas, George, Bamias, A. T., Dimopoulos, M. A., Kosmidis, Paraskevas A., Pavlidis, Nicholas

المساهمون: Pavlidis, Nicholas [0000-0002-2195-9961], Kalofonos, H. P. [0000-0002-3286-778X]

المصدر: Cancer chemotherapy and pharmacology

مصطلحات موضوعية: Drug dose regimen, Male, Lung Neoplasms, Toxicology, Gastroenterology, Antineoplastic Combined Chemotherapy Protocols, Pharmacology (medical), Treatment outcome, Etoposide, Survival time, Brain Neoplasms, Liver Neoplasms, Cisplatin/administration & dosage/adverse effects, Multicenter study, Clinical trial, Phase i, Oncology, Granulocyte colony stimulating factor, Cancer chemotherapy, Cohort analysis, Human, Diarrhea, medicine.medical_specialty, Bone marrow suppression, Clinical article, Febrile neutropenia, Liver Neoplasms/drug therapy/secondary, Bone Neoplasms, Maximum tolerated dose, Carcinoma, Small Cell/*drug therapy/pathology, Irinotecan, Article, Small-cell lung cancer, Lung Neoplasms/*drug therapy/pathology, Humans, Lung small cell cancer, neoplasms, Aged, Pharmacology, Cisplatin, Drug infusion, Confidence interval, Artery disease, Phase 1 clinical trial, Survival analysis, medicine.disease, Survival Analysis, Regimen, Brain neoplasms, Asthenia, Etoposide/administration & dosage/adverse effects, Atropine, Cancer Research, Camptothecin/administration & dosage/adverse effects/analogs & derivatives, Randomization, Lung neoplasms, Liver neoplasms, Furosemide, Ischemia, Nausea and vomiting, Brain Neoplasms/drug therapy/secondary, Small cell, Carcinoma, Small Cell, Middle aged, Fatigue, Priority journal, biology, Bone neoplasms, Middle Aged, Toxicity, Female, Abdominal cramp, medicine.drug, Adult, Neutropenia, Maximum Tolerated Dose, Chemotherapy induced emesis, Granisetron, Advanced cancer, Antineoplastic combined chemotherapy protocols, Internal medicine, Neurotoxicity, medicine, Lung cancer, business.industry, Topoisomerase, Carcinoma, Bone Neoplasms/drug therapy/secondary, Alopecia, Thrombosis, Thrombocytopenia, Cancer survival, Surgery, Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use, biology.protein, Camptothecin, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dff2618c16a6a2974616324845805afaTest
https://doi.org/10.1007/s00280-004-0994-8Test

المؤلفون: Briassoulis, E. Ch, Karavasilis, V., Tzamakou, E., Rammou, D., Soulti, K., Piperidou, C., Pavlidis, Nicholas

المساهمون: Pavlidis, Nicholas [0000-0002-2195-9961], Karavasilis, V. [0000-0002-5806-9399]

المصدر: Cancer chemotherapy and pharmacology

مصطلحات موضوعية: Male, Cancer Research, Docetaxel, Pharmacology, Toxicology, Polyethylene Glycols, Pegylated Liposomal Doxorubicin, Drug blood level, chemistry.chemical_compound, Doxorubicin/*administration & dosage/*pharmacokinetics, Controlled clinical trial, Antineoplastic Combined Chemotherapy Protocols, Drug Interactions, Pharmacology (medical), Paclitaxel/*administration & dosage, Quantitative analysis, Middle aged, Priority journal, Area under the curve, Liposome, biology, Polyethylene glycols, Middle Aged, Clinical trial, Antineoplastic agent, Oncology, Paclitaxel, Enzyme inhibitor, Female, Taxoids, Drug clearance, lipids (amino acids, peptides, and proteins), Drug carrier, Human, medicine.drug, Adult, Clinical article, Drug interaction, Data analysis, Article, Drug interactions, Pharmacokinetics, Antineoplastic combined chemotherapy protocols, Drug coating, Pegylated liposomal doxorubicin, Taxoid, medicine, Humans, Doxorubicin, Antineoplastic Combined Chemotherapy Protocols/*pharmacokinetics, Aged, Drug infusion, Taxane derivative, Phase 1 clinical trial, Taxoids/*administration & dosage, enzymes and coenzymes (carbohydrates), Malignant neoplastic disease, Macrogol, chemistry, Liposomes, Macrogol derivative, biology.protein, Cancer patient, Controlled study, High performance liquid chromatography

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acf8c01027ddb6014512733cf709d3b2Test
https://doi.org/10.1007/s00280-003-0750-5Test

المؤلفون: Pentheroudakis, George, Pappas, P., Golfinopoulos, Vassilis, Fountzilas, George, Nikolaidou, M., Boumba, V. A., Vougiouklakis, T., Nikiforidis, L., Tzamakou, E., Siarabi, O., Marselos, M., Pavlidis, Nicholas

المساهمون: Pavlidis, Nicholas [0000-0002-2195-9961], Pentheroudakis, George [0000-0002-6632-2462]

المصدر: Cancer chemotherapy and pharmacology

مصطلحات موضوعية: Drug dose regimen, Male, Treatment response, Toxicology, Deoxycytidine, Multiple cycle treatment, Drug blood level, Breast cancer, Antineoplastic agents, Medicine, Phase i trials, Pharmacology (medical), Prodrugs, Liver metastasis, Drug Administration Routes, Recommended drug dose, Clinical trial, Oncology, Fluorouracil, Administration, Drug intermittent therapy, Fluoropyrimidine, Human, Diarrhea, Oral, Clinical article, Drug fever, Antineoplastic Agents, derivatives/pharmacokinetics, Article, Drug Administration Schedule, Bile duct carcinoma, Capecitabine, Prodrugs/administration & dosage, Gastrointestinal symptom, Dose response, Humans, Adverse effect, Aged, Pharmacology, Lymph node metastasis, Maximum plasma concentration, Bone metastasis, Phase 1 clinical trial, Skin toxicity, medicine.disease, Colorectal cancer, Regimen, Erythema, Deoxycytidine/administration & dosage/adverse effects/*analogs &, Cancer Research, Skin erythema, Phases of clinical research, Administration, Oral, Cancer regression, Bolus (medicine), Neoplasms, Pancreas cancer, Drug absorption, Fatigue, Priority journal, Drug tolerability, Drug withdrawal, Solid tumor, Fluorouracil/administration & dosage/adverse effects/*analogs &, Anemia, Nausea, Middle Aged, Standard, Anorexia, Lung metastasis, Anesthesia, Fatigue/chemically induced, Female, Abdominal cramp, Simulation, medicine.drug, Adult, Neutropenia, Stomach cancer, Chemotherapy induced emesis, Drug half life, Pleura metastasis, Advanced cancer, Peritoneum metastasis, Antineoplastic Agents/*administration & dosage, Pharmacokinetics, Drug dose escalation, business.industry, Alopecia, Neoplasms/*drug therapy, Drug metabolite, Drug treatment failure, business, Constipation

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d992c1ec3d3408cd1bf11e9ca8d8c0c3Test
https://pubmed.ncbi.nlm.nih.gov/17333194Test